About ProKidney Corp.
https://www.prokidney.comProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates.
CEO
Bruce Culleton
Compensation Summary
(Year 2023)
Salary $244,961
Option Awards $8,345,464
Incentive Plan Pay $120,824
All Other Compensation $891
Total Compensation $8,712,140
Industry Biotechnology
Sector Healthcare
Went public June 30, 2021
Method of going public SPAC
Full time employees 204
ETFs Holding This Stock
Summary
Total 4
Showing Top 3 of 4
Ratings Snapshot
Rating : C
Discounted Cash Flow 3
Return On Equity 3
Return On Assets 1
Debt To Equity 1
Price To Earnings 1
Price To Book 1
Overall Score 2
Most Recent Analyst Grades
Grade Summary
Buy 3
Underperform 1
Showing Top 4 of 4
Price Target
Target High $6
Target Low $3
Target Median $5
Target Consensus $4.67
Institutional Ownership
BLACKROCK INC.
Shares:3.66M
Value:$8.34M
BROWN UNIVERSITY
Shares:1M
Value:$2.28M
MYDA ADVISORS LLC
Shares:450K
Value:$1.03M
Summary
% Of Shares Owned 4.51%
Total Number Of Holders 16
Showing Top 3 of 16
Market Cap $664.13 M
52w High $7.13
52w Low $0.46
P/E -4.15
Volume 471.89K
Outstanding Shares 124.00M
About ProKidney Corp.
https://www.prokidney.comProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $217K ▼ | $37.36M ▼ | $-16.47M ▲ | -7.59K% ▼ | $-0.12 ▲ | $-33.88M ▲ |
| Q2-2025 | $221K ▼ | $39.93M ▼ | $-16.55M ▲ | -7.49K% ▼ | $-0.13 | $-34.65M ▲ |
| Q1-2025 | $230K ▲ | $41.62M ▼ | $-16.73M ▲ | -7.28K% ▲ | $-0.13 ▲ | $-35.76M ▲ |
| Q4-2024 | $76K ▲ | $51.65M ▲ | $-21.28M ▼ | -28K% ▼ | $-0.17 ▼ | $-45.2M ▼ |
| Q3-2024 | $0 | $48.97M | $-17.91M | 0% | $-0.14 | $-41.91M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $271.73M ▼ | $351.61M ▼ | $33.27M ▲ | $-1.01B ▼ |
| Q2-2025 | $294.73M ▼ | $372.13M ▼ | $32.68M ▼ | $-1B ▼ |
| Q1-2025 | $328.5M ▼ | $406.06M ▼ | $36.08M ▼ | $-998.55M ▼ |
| Q4-2024 | $358.29M ▼ | $441.07M ▼ | $39.44M ▲ | $-994.95M ▼ |
| Q3-2024 | $406.81M | $474.79M | $31.32M | $-979.71M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-16.47M ▲ | $-26.6M ▲ | $29.02M ▲ | $7.96M ▲ | $10.38M ▲ | $-31.79M ▲ |
| Q2-2025 | $-36.97M ▲ | $-31.42M ▼ | $18.57M ▼ | $-14K ▼ | $-12.87M ▼ | $-34.53M ▼ |
| Q1-2025 | $-37.95M ▲ | $-29.59M ▼ | $28.29M ▲ | $-12K ▼ | $-1.31M ▲ | $-30.73M ▲ |
| Q4-2024 | $-48.48M ▼ | $-24.17M ▲ | $15.08M ▲ | $123K ▼ | $-8.97M ▲ | $-49.68M ▼ |
| Q3-2024 | $-41.05M | $-29.24M | $-81.64M | $4.46M | $-106.42M | $-31.64M |
CEO
Bruce Culleton
Compensation Summary
(Year 2023)
Salary $244,961
Option Awards $8,345,464
Incentive Plan Pay $120,824
All Other Compensation $891
Total Compensation $8,712,140
Industry Biotechnology
Sector Healthcare
Went public June 30, 2021
Method of going public SPAC
Full time employees 204
ETFs Holding This Stock
Summary
Total 4
Showing Top 3 of 4
Ratings Snapshot
Rating : C
Discounted Cash Flow 3
Return On Equity 3
Return On Assets 1
Debt To Equity 1
Price To Earnings 1
Price To Book 1
Overall Score 2
Most Recent Analyst Grades
Grade Summary
Buy 3
Underperform 1
Showing Top 4 of 4
Price Target
Target High $6
Target Low $3
Target Median $5
Target Consensus $4.67
Institutional Ownership
BLACKROCK INC.
Shares:3.66M
Value:$8.34M
BROWN UNIVERSITY
Shares:1M
Value:$2.28M
MYDA ADVISORS LLC
Shares:450K
Value:$1.03M
Summary
% Of Shares Owned 4.51%
Total Number Of Holders 16
Showing Top 3 of 16